Vazyme Biotech closes RMB550m Series C round

Vazyme Biotech announced the completion of 550 million yuan Series C round of financing, exclusively led by China Life Private Equity, with participation from Sherpa Venture Capital and other institutions.
Established in 2012, Vazyme Biotech, Vazyme Biotech is one of the few high-tech enterprises in China that has independent research and development capabilities for key raw materials in biotech

Vazyme Biotech announced the completion of 550 million yuan Series C round of financing, exclusively led by China Life Private Equity, with participation from Sherpa Venture Capital and other institutions.

Established in 2012, Vazyme Biotech, Vazyme Biotech is one of the few high-tech enterprises in China that has independent research and development capabilities for key raw materials in biotechnology.

It has become a technology platform company integrating the development, production and sales of enzymes, antigens, antibodies and terminal reagents which are key common technologies in life sciences, in vitro diagnostics, and biomedicine.

With a forward-looking vision and requirements of the international leading technology, Vazyme Biotech spent huge sums to build 25,000-square-meter R&D base and 4,000-square-meters aseptic purification production workshop of IVD beyond the GMP standards.

In the mean time, the company also established marketing centers in China’s first-tier cities such as Beijing, Shanghai and Guangzhou and set up sales network around the whole country.

Dr. Cao Lin, Chairman of Vazyme Biotech said: “After the completion of this financing round, the company will continue to deepen the industrialization of core key raw materials and reagents in the field of biotechnology, and at the same time expand to more downstream application areas. “

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/11/vazyme-biotech-closes-rmb550m-series-c-round/.

Leave a Reply

Please Login to Comment